Page 2 - Ipca Laboratories

Lyka Labs hits 5% upper circuit after Ipca buys 1 mn shares via bulk deals

On Monday, Ipca Laboratories purchased 1.05 million equity shares representing 3.65 per cent stake in Lyka Labs at price of Rs 123 per share on the BSE via bulk deals

Ipca Labs second quarter net profit declines 6% to Rs 250 crore

The board declared an interim dividend of Rs 8 per share

3 stock ideas by Osho Krishan of Anand Rathi: Buy Havells, Ipca Labs

Motherson Sumi's stock has seen some buying interest in the past trading sessions and settled well above all its major moving averages on the daily time frame

Drug firm Ipca Laboratories fourth quarter profit up 94% at Rs 161 crore

Shares of Ipca Laboratories were trading at Rs 2,132.30 per scrip on BSE, down 3.06 per cent from the previous close.

Bull run continues; Sensex up 316 pts to end at 43,594, Nifty nears 12,750

All that happened in the markets today.

Pharma shares underperform in a firm market; Glenmark, Ipca Labs fall 6%

In the past month, the S&P BSE Healthcare index underperformed the market by falling 5 per cent, as compared to 5.4 per cent rise in the S&P BSE Sensex

In process of obtaining environmental clearance for new plant in MP: Ipca

Drug maker Ipca Laboratories is in the process of obtaining environmental clearance for a new manufacturing plant in Dewas, Madhya Pradesh, according to its 2019-20 annual report.

Ipca Labs Q1 profit jumps more than 3-folds to Rs 445.68 cr on robust sales

The company had posted a net profit of Rs 129.43 crore for the corresponding period of the previous fiscal, Ipca Labs said in a BSE filing

Ipca Lab hits 52-week high in a range-bound market; stk surges 9% in 3 days

According to Analysts at Phillip Capital, the company's revenues could grow 18 per cent year-on-year (YoY) to Rs 1,272.5 crore in June quarter of FY21

11,300 key level for Nifty ahead of F&O expiry: CapitalVia Global Research

The level of 11,000 might act as support

Domestic growth remains a highlight in IPCA Laboratories' Q4 show

14-17% top line growth estimate indicates 20% rise in earnings

Antiviral drugs see demand surge in India, but segment declines 5.5%

Data from market research firm AIOCD-AWACS shows that sales of oseltamivir (common brand Tamiflu), used against the influenza virus and also for swine flu, went up by 35.8 per cent in April

Ipca and Cadila Healthcare gear up to make drug for coronavirus

Ipca is the biggest producer of the drug. Cadila Healthcare, based in Ahmedabad, too is a major player

Ipca Labs' outlook remains intact with India business on strong footing

Outlook remains intact with India business on strong footing, exports supported by ingredient capabilities

Uptick in domestic segment, biz growth continue to drive Ipca Laboratories

Further rerating of stock will hinge on USFDA resolution

Strong domestic and export growth to drive Ipca Laboratories' earnings

Ipca's first half performance holds testimony to its robust growth with India business growing in mid-teens

US FDA pulls up Ipca Labs for manufacturing violations at Gujarat plant

The United States Food and Drug Administration (USFDA) inspection of its Piparia (Silvassa) formulations manufacturing unit in August resulted in three observations, it added.

Optimism on Europe, India biz to offset US sales losses for Ipca Labs

Analysts see 13.4% annual growth in domestic business over FY18-21

Ipca on recovery path over FDA clearance, growth in Africa tender business

The stock was trading at 17 times its 2020 earnings estimates

Ipca Labs hits 52-week high; up 21% in 11 days post Q3 results

The stock hit a 52-week high of Rs 671, up 5% on the BSE in otherwise weak market.